2
Clinical Trials associated with Menstrual blood derived mesenchymal stem cells ( Innovative Precision Medicine Group) / Active, not recruitingPhase 1 评价宫血间充质干细胞(SC01009)注射液在特发性肺纤维化患者中的安全性、耐受性、PK/PD和初步有效性的单、多次给药剂量递增及扩展的I期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability, PK/PD and preliminary efficacy of single and multiple dose escalation and expansion of uterine blood mesenchymal stem cell (SC01009) injection in patients with idiopathic pulmonary fibrosis
主要目的:评价宫血间充质干细胞(SC01009)注射液在特发性肺纤维化患者中单、多次给药的安全性。
次要目的:初步评价宫血间充质干细胞(SC01009)注射液在特发性肺纤维化患者中的有效性。
探索性目的:评价宫血间充质干细胞(SC01009)注射液在特发性肺纤维化患者中单、多次给药的药代动力学(PK)、药效学(PD)及免疫学特征。
[Translation] Primary objective: To evaluate the safety of single and multiple administrations of uterine blood mesenchymal stem cell (SC01009) injection in patients with idiopathic pulmonary fibrosis.
Secondary objective: To preliminarily evaluate the effectiveness of uterine blood mesenchymal stem cell (SC01009) injection in patients with idiopathic pulmonary fibrosis.
Exploratory objective: To evaluate the pharmacokinetic (PK), pharmacodynamic (PD) and immunological characteristics of single and multiple administrations of uterine blood mesenchymal stem cell (SC01009) injection in patients with idiopathic pulmonary fibrosis.
/ SuspendedEarly Phase 1IIT Basic and clinical study for intrauterine transplantation with autologous platelet-rich plasma combined with of mesenchymal blood-derived stem cells for endometrial injury
Start Date30 Jan 2020 |
Sponsor / Collaborator- |
100 Clinical Results associated with Menstrual blood derived mesenchymal stem cells ( Innovative Precision Medicine Group)
100 Translational Medicine associated with Menstrual blood derived mesenchymal stem cells ( Innovative Precision Medicine Group)
100 Patents (Medical) associated with Menstrual blood derived mesenchymal stem cells ( Innovative Precision Medicine Group)
100 Deals associated with Menstrual blood derived mesenchymal stem cells ( Innovative Precision Medicine Group)